Cargando…

Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial

BACKGROUND: Pembrolizumab alone or in combination with chemotherapy is a standard treatment for patients with non‐small‐cell lung cancer (NSCLC) with high programmed death‐ligand 1 (PD‐L1) expression. However, no study has compared the efficacies of these two regimens. Therefore, we aimed to compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, Hiromi, Kobayashi, Nobuaki, Somekawa, Kohei, Fukuda, Nobuhiko, Kaneko, Ayami, Kamimaki, Chisato, Kubo, Sousuke, Tanaka, Katsushi, Tagami, Yoichi, Teranishi, Shuhei, Watanabe, Keisuke, Horita, Nobuyuki, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Koizumi, Harumi, Miura, Kenji, Miyazawa, Naoki, Kaneko, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758435/ https://www.ncbi.nlm.nih.gov/pubmed/34866339 http://dx.doi.org/10.1111/1759-7714.14252

Ejemplares similares

T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer
por: Kamimaki, Chisato, et al.
Publicado: (2021)

Regional differences in epidermal growth factor receptor-tyrosine kinase inhibitor therapy in lung cancer treatment using a national database in Japan
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis
por: Matsumoto, Hiromi, et al.
Publicado: (2023)

MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer
por: Katakura, Seigo, et al.
Publicado: (2020)

Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer
por: Teranishi, Shuhei, et al.
Publicado: (2020)

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis
por: Kobayashi, Nobuaki, et al.
Publicado: (2021)

Best regimens for treating chemo‐naïve incurable squamous non‐small cell lung cancer with a programmed death‐ligand 1 tumor proportion score of 1%–49%: A network meta‐analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis
por: Fukuda, Nobuhiko, et al.
Publicado: (2021)

Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study
por: Fujii, Hiroaki, et al.
Publicado: (2022)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes
por: Kobayashi, Nobuaki, et al.
Publicado: (2023)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
por: Kobayashi, Nobuaki, et al.
Publicado: (2020)

Computed tomography imaging‐based observation of the aggressive growth of angiosarcoma: a case study
por: Kubo, Sousuke, et al.
Publicado: (2019)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

Diagnostic utility of transbronchial biopsy for Hodgkin's lymphoma: A case study
por: Hoshi, Miki, et al.
Publicado: (2021)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
por: Isono, Taisuke, et al.
Publicado: (2021)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient
por: Matsumoto, Sachiko, et al.
Publicado: (2020)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis
por: Nakamura, Kazunori, et al.
Publicado: (2023)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Pembrolizumab-Induced Delayed-Onset Hepatitis
por: Kanaoka, Kensuke, et al.
Publicado: (2020)

A functionally improved case of obstructive impairment caused by systemic lupus erythematosus
por: Kamimaki, Chisato, et al.
Publicado: (2021)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance
por: Nishiyama, Hiroyuki, et al.
Publicado: (2023)

The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease
por: Nishikawa, Yurika, et al.
Publicado: (2021)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
por: Terai, Hideki, et al.
Publicado: (2022)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Real‐world outcomes of pembrolizumab monotherapy in non‐small cell lung cancer in Japan: A post‐marketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2022)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
por: Nishio, Shin, et al.
Publicado: (2020)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
por: Gohara, Kazuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_57e1a4csul8lb4b5qpi7ftdtck